Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

A significant shake-up of distributors in the Indian market impacted Cipla’s first-quarter earnings but the firm expects to bounce back. Biosimilars in emerging markets and opportunities in China are among the growth drivers it is banking on.

Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

As it prepares to start injectables filings from its facility in Buena, New Jersey, Teligent is putting in place its senior operational and quality functions. 

Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Three key areas for improvement in in the FDA’s draft guidance on therapeutic protein biosimilars have been highlighted by industry association AAM. Pharmaceutical giants such as Pfizer, Novartis and Celltrion have also expressed concerns highlight shortcomings and sought clarification.

Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.

Launching the oncology drug bortezomib in 14 European countries helped Stada to record an 11% increase in both Generics and group sales in the first half of 2019. But the German group, which is about to start rolling out biosimilar teriparatide, has suffered a legal setback on pemetrexed in its home market.

An operating loss recorded by its US Sagent affiliate depressed Nichi-Iko’s group operating margin to just 3.7%, even though the Japanese generics specialist’s turnover increased by a tenth on strong domestic generics demand.

Teva’s finance chief Mike McClellan is leaving the company in November. But he maintains his departure is solely due to personal reasons.

Endo has named a head for its sterile injectables and generics operations; Hikma has appointed an R&D head; Acino has a new leader for its Latin American business; Alvogen has appointed a general counsel; and Julphar has shaken up its senior management team.

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.